Mylan Agrees to Hand Over EpiPen Documents to Congress

Monitor pharmaceutical companies taking advantage of the huge demand for their products by hiking prices steeply, of which, the needy patient can do nothing at all, but still buy. A matter of life and death. Not only Epipen.


Mylan [fortune-stock symbol=”myl”] has been in the hot seat since reports of its extravagant price hikes for the EpiPen, a device which millions of Americans, including 1 in 13 children, rely on as a life-saving backstop, emerged last month.

Now, the company has agreed to hand over documents to indignant lawmakers seeking to probe its pricing practices, CNN reports.

Click hereto subscribe to our upcoming Brainstorm Health Daily Newsletter.

Several members of Congress have been demanding more information from the generic drug giant about its pricing practices since the EpiPen scandal broke. Some, including Minnesota Sen. Amy Klobuchar, have even called for Federal Trade Commission (FTC) investigations into the company.

The U.S. House Committee on Oversight and Government Reform specifically asked for more detailed information about Mylan’s pricing habits, including discounts given to patients, at the end of August. The firm was asked to submit the documentation by the…

View original post 79 more words


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s